Research Study


Study Status: Currently Not Enrolling

Study Name:   BIDI  

Study Focus:   Overweight and Obese Individuals with Type II Diabetes

Study Contact: To learn more, please call 1-877-854-8475 or fill out the Contact us form

Study Purpose:  To evaluate the effectiveness and safety of an investigational drug, Bimagrumab (study drug) compared to placebo to decrease total body fat mass, increase muscle mass and improve glycemic control in overweight and obese individuals with type 2 diabetes.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria:

  • BMI 28 - 40
  • 18 - 75 years of age HbA1C between 6.5% - 10%
  • Currently taking only Metformin, only a DPP4 inhibitor, a combination of Metformin and a DPP4 inhibitor, or no anti-diabetes medication at all for  approximately 3 months

Study Duration: Approximately 56 weeks

Study Commitment:

  • 2 Screening visits
  • Total of 16 Outpatient Visits (Study drug or placebo dosing for 12 visits and 3 non-dosing visits) 
  • Total of 12 Phone Calls

Study Procedures:

  • Physical exam, vital signs, height, and weight, EKG
  • DXA and MRI (optional)
  • IV insertion
  • Blood and Urine Collections
  • Dietary Counseling
  • Physicial Performance Testing
  • Physical Activity Monitoring
  • Mixed Meal Tolerance Test

Compensation offered up to $ 4,400

This study is being conducted under the direction of Dr. Bret Goodpaster, at 301 East Princeton Street, Orlando, Florida 32804.